Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 9Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Intraocular Lymphoma 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

prednylidene 1glofitamab 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1auricularum 1Vincristine 1Specimen Handling 1Rituximab 1Prednisone 1Platinum 1Magnetic Resonance Spectroscopy 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Calcium Dobesilate 1CT-P10 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ann Arbor Stage II Mantle Cell Lymphoma × Rituximab × Clear all
NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡